Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Non-Current Deffered Revenue (2017 - 2022)

Denali Therapeutics (DNLI) has disclosed Non-Current Deffered Revenue for 6 consecutive years, with $479000.0 as the latest value for Q4 2022.

  • Quarterly Non-Current Deffered Revenue fell 85.9% to $479000.0 in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $479000.0 through Dec 2022, down 85.9% year-over-year, with the annual reading at $479000.0 for FY2022, 85.9% down from the prior year.
  • Non-Current Deffered Revenue for Q4 2022 was $479000.0 at Denali Therapeutics, down from $3.4 million in the prior quarter.
  • The five-year high for Non-Current Deffered Revenue was $57.4 million in Q4 2018, with the low at $479000.0 in Q4 2022.
  • Average Non-Current Deffered Revenue over 5 years is $28.7 million, with a median of $31.3 million recorded in 2021.
  • The sharpest move saw Non-Current Deffered Revenue surged 811.19% in 2018, then crashed 89.15% in 2022.
  • Over 5 years, Non-Current Deffered Revenue stood at $57.4 million in 2018, then decreased by 23.71% to $43.8 million in 2019, then plummeted by 46.69% to $23.3 million in 2020, then tumbled by 85.43% to $3.4 million in 2021, then crashed by 85.9% to $479000.0 in 2022.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods came in at $479000.0, $3.4 million, and $3.4 million for Q4 2022, Q2 2022, and Q1 2022 respectively.